**Specifications Table**TableSubject area*Biology*More specific subject area*Cancer genomics*Type of data*Table and Figure*How data was acquired*Oligo-based array-comparative genomic hybridization (oaCGH) was used to examine for copy number alterations*Data format*Analyzed*Experimental factors*Purified DNA from bone marrow samples at the time of acute monocytic leukemia diagnosis and at the time of complete remission were compared*Experimental features*Direct comparison by oaCGH analysis using purified DNA from time of complete remission as reference DNA allows to distinguishing whether observed copy number alterations are true copy number alterations or normal copy number variations*Data source location*Aarhus, Denmark*Data accessibility*Data is with this article*

**Value of the data**•Copy number alterations in subtelomeric regions examined by oaCGH analysis are rarely reported in leukemic genomes•Copy number variations are common in subtelomeric regions when foreign DNA is used as reference DNA making it impossible to distinguish these from true copy number alterations•Direct comparison of patient׳s leukemic DNA with purified DNA from the time of complete remission allows for reporting of all copy number aberrations fulfilling basic criteria for them to be called•The findings add to the spectrum of subtelomeric copy number alterations associated with JT

1. Data {#s0005}
=======

Copy number alterations at subtelomeric regions were examined. Thirty one out of 92 subtelomeric regions (33.7%) had duplications between 141,682 and 864,400 bp in size (mean size 298,957 bp) as summarized in [Table 1](#t0005){ref-type="table"}. The genomic profiles of all subtelomeric chromosomal regions are shown in [Fig. 1](#f0005){ref-type="fig"}. A search in the UCSC bioinformatics database revealed a total of 177 genes in the subtelomeric regions with segmental duplications ([Table 2](#t0010){ref-type="table"}).Fig. 1Zoom-in view of telomeric p- and q-regions of individual chromosomes 1-22 and the X-chromosome of oaCGH analysis using DNA from diagnosis and DNA from complete remission as reference. The x-axis indicates genomic positions and the y-axis indicates the log2 ratios. Blue shades indicate gained regions.Fig. 1Table 1Subtelomeric copy number alterations in the blast cells.Table 1ChromosomeCytobandGenomic position (bp)[a](#tbl1fna){ref-type="table-fn"}Size (Mb)Copy number aberration1p36.33\
q441 - 864,399\
246,909,654 -- 247,249,7190.86\
0.34Gain\
Gain2p25.3\
q37.31 - 168,438\
242,618,961 -- 242,951,1490.17\
0.33Gain\
Gain4p16.31 - 259,4960.26Gain5p15.33\
q35.31- 350,106\
180,403,896 -- 180,857,8660.35\
0.45Gain\
Gain6p25.3\
q271 - 240,983\
170,743,310 -- 170,899,9920.24\
0.16Gain\
Gain7p22.3\
q36.31 - 317,221\
158,527,361 -- 158,821,4240.32\
0.29Gain\
Gain8p23.3\
q24.31 - 158,984\
145,836,948 -- 146,274,8260.16\
0.44Gain\
Gain10q26.3135,156,343 -- 135,374,7370.22Gain11q25134,158,206 -- 134,452,3840.29Gain12p13.33\
q24.331 - 248,197\
132,134,110 -- 132,349,5340.25\
0.22Gain\
Gain13q34113,707,862 -- 114,142,9800.44Gain15q26.3100,135,399 -- 100,338,9150.20Gain16p13.3\
q24.31 - 141,681\
88,600,659 -- 88,827,2540.14\
0.23Gain\
Gain17p13.31 - 353,8780.35Gain18p11.32\
q231 - 266,608\
75,796,416 -- 76,117,1530.27\
0.32Gain\
Gain19p13.3\
q13.431 - 430,031\
63,549,249 -- 63,811,6510.43\
0.26Gain\
Gain20p13\
q13.331-185,691\
62,142,263 -- 62,435,9640.19\
0.29Gain\
Gain21q22.346,677,243 -- 46,944,3230.27GainXp22.33\
q281 - 412,524\
154,690,971 -- 154,913,7540.41\
0.22Gain\
Gain[^1]Table 2Genes located in the subtelomeric regions within identified segmental duplications.Table 2ChromosomeUCSC RefSeq Genes11p: *DOX11L1, WASH7P, MIR6859, MIR6723, FAM87B, FAM138A, LINC00115, LINC01128, ORF4, ORF29*\
1q: *SCCPHD, LINC01341, AHCTF1, ZNF670-695, ZNF670*22p: *FAM110C*\
2q: *DTYMK, ING5, D2HGDH, GAL3ST2, PABL, NEU4, PDCD1, CXXC11*44p: *ZNF595, ZNF718, ZNF876P*55p: *PLEKHG4B, LRRC14B, CCDC127, SDHA, HRAT5, PDCD6, AHRR*\
5q: *CNO6, SCG3A1, FLT4, ORY1, MGAT1, HEIH, ZFP62*66p: *LINC00266-3*\
6q: *PSMB1, TBP, PDCD2*77p: *LOC10723672, LOC100507642, LOC105375115, FAM20C*\
7q: *ESYT2, WDR60, LINC00689, VIPR*88p: *OR4F21*\
8q: *ARHGAP39, ZNF251, RPL8, ZNF34, ZNF7, MIR6850, COMMD5, ZNF250, ZNF16, ZNF252P, TMED10P1, ZNF252P-AS*1010q: *PRAP1, FUOM, MIR3944, ECHS1, PAOX, MTG1, SPRN, SCART1, CYP2E1, SYCE1*1111q: *GLB1L3, GLB1L2, B3GAT1, LOC283177*1212p: *FAM138D, DDX11L1, LOC100288778, IQSEC. 3*\
12q: *SFSWAP, MMP17*1313q: *MCF2L, F7, F10, PROZ, PCID2, CUL4A, MIR8075, LAMP1, GRTP1, ADPRHL1, LOC101928841, DCUN1D2*1515q: *MEF2A, LYSMD4*1616p: *DDX11L10, MIR6859, WASIR2, POLR3K, SNRNP25, RHBDF1, MPG, NPRL3*\
16q: *ZC3H18, IL17C, CYBA, SNAI3, MVD, RNF166, CTU2, MIR4722, PIEZO1, LOC100289580*1717p: *DOC2B, RPH3AL, LINC02091, LOC100506388, LOC105371430, C17orf97, RFLNB*1818p: *DUX4, LOC102723376, MIR8078, ROCK1P1, USP14, THOC1*\
18q: None1919p: *WASH5P, MIR1302, FAM138A, FAM138F, OR4F17, LINC01002, PLPP2, MIER2, THEG, C2CD4C, SHC2*\
19q: *ZNF8, ZBTB45, A1BG, MZF1*2020p: *DEFB125, DEFB126, DEFB127, DEFB128*\
20q: *PPDPF, PTK6, FNDC11, HELZ2, GMEB2, MHENCR, STMN3, RTEL1, ARFRP1, TNFRSF6B, ZGPAT, LIME1, SLC2A4RG, ZBTB46*2121q: *LINC00334, POFUT2, LINC00316, COL18A1, MIR6815, SLC19A1*XXp: *PLCXD1, GTPBP6, LINC00685, PPP2R3B*\
Xq: *TMLHE, LOC101927830, SPRY3*

2. Experimental design, materials and methods {#s0010}
=============================================

By oaCGH analysis using purified DNA from aspirated bone marrow at the time of diagnosis and purified DNA from aspirated bone marrow at the time of complete remission as reference DNA we recently characterized the 3q13.31 breakpoint region in an adult with *de novo* acute monocytic leukemia harboring an acquired JT involving the 3q13.31-qter chromosomal region [@bib1]. This experimental design allows for a direct comparison between the patient׳s bone marrow cells at diagnosis and at complete remission eliminating interpretations of possible copy number variations, which are known to be common in subtelomeric regions [@bib2]. Such a direct comparison allows for reporting of all copy number aberrations, which fulfills the basic criteria for them to be called. Reference genome was NCBI build 37 (hg19) and the University of California Santa Cruz (UCSC) database (<http://genome.ucsc.edu>) was used for bioinformatics analysis.

The biotechnologists Bente Madsen and Pia Kristensen are greatly thanked for their excellent technical assistance with the oaCGH analysis.

[^1]: Genomic positions are given according to NCBI build 36.1 (hg18).
